EVH on NYSE

Evolent Health, Inc.

Evolent is a market leader in connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses.⁴ From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Gartner, FranklinCovey or Kioni Holdings Ltd, or pick any stock.

TickerEVH on NYSE²
IndustryServices-Management Services²
HeadquartersArlington, United States²
Incorporated inDE³
Business address1812 North Moore St, Suite 1705, Arlington, Va 22209³
Filer categoryLarge accelerated filer³
Legal formCorporation²
LEI549300CZOCFHQ2BBTR11²
StatusActive²
LEI statusLapsed (not renewed)²
Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States²
Registered withDivision of Corporations, Department of State, 5657253²

See how the biggest companies compare on our leaderboards

Evolent is a market leader in connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. We work on behalf of health plans and other risk-bearing entities and payers (our customers) to support physicians and other healthcare providers (our users) in providing high quality evidence-based care to their patients. We believe adherence to evidence-based clinical pathways supports better outcomes for patients, a better experience for physicians, and lower costs for the healthcare system overall.⁴ From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-21.9%Operating margin⁵

-28.5%Net margin⁵

-26.6%Revenue growth, 2025⁵

-128.7%Return on equity⁵

2.34×Debt to equity⁵

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Business segments

Evolent Health Services brought in 50% of the revenue Evolent Health, Inc. broke down this way in fiscal 2025.

Evolent Health Services$1.9B⁵50%down 27% from 2024
Reportable$1.9B⁵50%down 27% from 2024

Business segments by year

Business segments	2023	2024	2025
Evolent Health Services	$2.0B	$2.6B	$1.9B
Reportable	$2.0B	$2.6B	$1.9B

Where the money goes

Where each dollar of revenue went, fiscal 2025

Cost of revenueSelling, general and admin

Cost of revenue79¢$1.5B
Selling, general and admin16¢$303.9M
Other costs5¢$95.9M
Income tax0¢$126.0K

Out of $1.9B in revenue.⁵ The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

Share buybacks

Share buybacks100¢$40.0M

Out of $38.8M of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.⁵

Financial statements

Revenue⁶⁷⁸⁹⁵$1.9B in 2025+122% since 2019

Operating income¹⁰⁷⁸⁹⁵-$410.1M in 2025+33% since 2019

Net income⁶⁷⁸⁹⁵-$534.5M in 2025+77% since 2019

Every line of the income statement as filed: the last 3 fiscal years (annual) or 8 quarters (quarterly), latest first.⁵

Period ending	2025-12-31	2024-12-31	2023-12-31
Revenue	$1.9B	$2.6B	$2.0B
Cost of revenue	$1.5B	$2.2B	$1.5B
Selling, general and administrative expenses	$303.9M	$263.1M	$358.1M
Depreciation and amortization expenses	$115.9M	$118.4M	$123.4M
Loss on lease termination	$676.0K	$18.9M	$0
(Gain) loss on disposal of non-strategic assets	-$14.9M	$0	$8.1M
Right-of-use asset impairment	$0	$2.6M	$24.1M
Goodwill impairment	$398.0M	$0	$0
Change in fair value of contingent consideration	$6.5M	$4.9M	$18.0M
Operating expenses	$2.3B	$2.6B	$2.0B
Operating loss	-$410.1M	-$40.5M	-$71.2M
Interest income	$4.2M	$5.5M	$5.3M
Interest expense	-$57.5M	-$24.7M	-$54.2M
Gain (loss) from equity method investees	$365.0K	-$3.4M	$1.3M
Loss on extinguishment/repayment of debt	-$3.5M	$0	-$21.0M
Loss on option exercise	-$52.5M	$0	$0
Extinguishment of Series A Preferred Stock and other refinancing fees	-$15.0M	$0	$0
Change in tax receivables agreement liability	-$804.0K	-$173.0K	-$62.0M
Other expense, net	$249.0K	$241.0K	-$543.0K
Loss before income taxes	-$534.6M	-$63.0M	-$202.4M
Benefit from income taxes	-$126.0K	-$1.4M	-$89.4M
Income (loss) before preferred dividends and accretion of Series A Preferred Stock	-$534.5M	-$61.6M	-$113.0M
Dividends and accretion of Series A Preferred Stock including excise tax	-$44.9M	-$31.8M	-$29.2M
Net loss attributable to common shareholders of Evolent Health, Inc. - basic	-$579.4M	-$93.5M	-$142.3M
Net loss attributable to common shareholders of Evolent Health, Inc. - diluted	-$579.4M	-$93.5M	-$142.3M
Basic (in dollars per share)	-$5.07	-$0.81	-$1.28
Diluted (in dollars per share)	-$5.07	-$0.81	-$1.28
Basic (in shares)	114.2M shares	114.7M shares	111.3M shares
Diluted (in shares)	114.2M shares	114.7M shares	111.3M shares
Foreign currency translation adjustment	-$871.0K	-$496.0K	-$79.0K
Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.	-$580.3M	-$94.0M	-$142.3M

Period ending	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31
Revenue	$468.7M	$479.5M	$444.3M	$483.6M	$646.5M	$621.4M	$647.1M	$639.7M
Operating expenses	$877.0M	$478.6M	$445.5M	$485.3M	$665.1M	$637.7M	$639.4M	$653.1M
Income (loss) before preferred dividends and accretion of Series A Preferred Stock	-$429.1M	-$20.9M	-$19.9M	-$64.6M	-$22.8M	-$23.1M	$1.6M	-$17.3M
Dividends and accretion of Series A Preferred Stock including excise tax	$0	-$6.1M	-$31.2M	-$7.6M	-$7.8M	-$8.1M	-$8.0M	-$7.9M
Net loss attributable to common shareholders of Evolent Health, Inc. - basic	-$429.1M	-$26.9M	-$51.1M	-$72.2M	-$30.6M	-$31.2M	-$6.4M	-$25.2M
Net loss attributable to common shareholders of Evolent Health, Inc. - diluted	-$429.1M	-$26.9M	-$51.1M	-$72.2M	-$30.6M	-$31.2M	-$6.4M	-$25.2M
Basic (in dollars per share)	-$3.84	-$0.24	-$0.44	-$0.63	-$0.27	-$0.27	-$0.06	-$0.22
Diluted (in dollars per share)	-$3.84	-$0.24	-$0.44	-$0.63	-$0.27	-$0.27	-$0.06	-$0.22

Total assets⁶¹⁰⁷⁸⁹⁵$1.9B in 2025+27% since 2019

Total liabilities⁶¹⁰⁷⁸⁹⁵$1.5B in 2025+161% since 2019

Shareholders’ equity⁷⁹⁵$415.2M in 2025−55% since 2019

Cash⁶¹⁰⁷⁸⁹⁵$151.9M in 2025+50% since 2019

Long-term debt⁶¹⁰⁷⁸⁹⁵$970.5M in 2025+230% since 2019

Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.⁵

Period ending	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Cash and cash equivalents	$151.9M	$104.2M
Restricted cash	$26.1M	$59.3M
Accounts receivable, net	$309.9M	$414.7M
Prepaid expenses and other current assets	$18.5M	$28.9M
Total current assets	$506.4M	$607.1M
Restricted cash	$2.7M	$15.0M
Investments and equity method investees	$9.0M	$8.6M
Property and equipment, net	$80.8M	$73.2M
Right-of-use assets - operating	$4.4M	$6.1M
Prepaid expenses and other noncurrent assets (1)	$3.1M	$3.6M
Contract cost assets	$13.5M	$13.4M
Intangible assets, net	$584.9M	$680.2M
Goodwill	$694.5M	$1.1B	$1.1B	$722.8M
Total assets	$1.9B	$2.5B
Accounts payable	$59.8M	$96.0M
Accrued liabilities (1)	$65.8M	$66.4M
Operating lease liability - current	$15.3M	$26.7M
Accrued compensation and employee benefits	$51.0M	$33.7M
Deferred revenue	$1.2M	$2.5M
Short-term debt, net	$0	$171.5M
Reserve for claims and performance - based arrangements	$192.2M	$318.7M
Total current liabilities	$385.3M	$715.5M
Long-term debt, net	$970.5M	$490.5M
Other long-term liabilities	$8.0M	$3.0M
Tax receivables agreement liability	$108.9M	$108.1M
Operating lease liabilities - noncurrent	$3.8M	$25.0M
Deferred tax liabilities, net	$7.5M	$10.9M
Total liabilities	$1.5B	$1.4B
Preferred class A common stock - $0.01 par value; 50,000,000 shares authorized; 0 and 175,000 issued, respectively	$0	$190.2M	$178.4M	$0
Class A common stock - $0.01 par value; 750,000,000 shares authorized; 117,603,806 and 116,575,773 shares issued, respectively	$1.2M	$1.2M
Additional paid-in-capital	$1.8B	$1.8B
Accumulated other comprehensive loss	-$2.6M	-$1.8M
Retained earnings (accumulated deficit)	-$1.3B	-$780.8M
Treasury stock, at cost; 5,971,712 and 1,537,582 shares issued, respectively	-$61.4M	-$21.1M
Total shareholders equity	$415.2M	$1.0B	$1.1B	$859.4M
Total liabilities, mezzanine equity and shareholders equity	$1.9B	$2.5B
Preferred class A common stock, par value (in dollars per share)	$0.01	$0.01
Preferred class A common stock, shares authorized (in shares)	50.0M shares	50.0M shares
Preferred class A common stock, shares issued (in shares)	0 shares	175.0K shares	175.0K shares	0 shares
Class A common stock, par value (in dollars per share)	$0.01	$0.01
Class A common stock, shares authorized (in shares)	750.0M shares	750.0M shares
Class A common stock, shares issued (in shares)	117.6M shares	116.6M shares
Treasury stock, shares issued (in shares)	6.0M shares	1.5M shares

Period ending	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Cash and cash equivalents	$151.9M	$104.2M
Restricted cash	$26.1M	$59.3M
Accounts receivable, net	$309.9M	$414.7M
Prepaid expenses and other current assets	$18.5M	$28.9M
Total current assets	$506.4M	$607.1M
Restricted cash	$2.7M	$15.0M
Investments and equity method investees	$9.0M	$8.6M
Property and equipment, net	$80.8M	$73.2M
Right-of-use assets - operating	$4.4M	$6.1M
Prepaid expenses and other noncurrent assets (1)	$3.1M	$3.6M
Contract cost assets	$13.5M	$13.4M
Intangible assets, net	$584.9M	$680.2M
Goodwill	$694.5M	$1.1B	$1.1B	$722.8M
Total assets	$1.9B	$2.5B
Accounts payable	$59.8M	$96.0M
Accrued liabilities (1)	$65.8M	$66.4M
Operating lease liability - current	$15.3M	$26.7M
Accrued compensation and employee benefits	$51.0M	$33.7M
Deferred revenue	$1.2M	$2.5M
Short-term debt, net	$0	$171.5M
Reserve for claims and performance - based arrangements	$192.2M	$318.7M
Total current liabilities	$385.3M	$715.5M
Long-term debt, net	$970.5M	$490.5M
Other long-term liabilities	$8.0M	$3.0M
Tax receivables agreement liability	$108.9M	$108.1M
Operating lease liabilities - noncurrent	$3.8M	$25.0M
Deferred tax liabilities, net	$7.5M	$10.9M
Total liabilities	$1.5B	$1.4B
Preferred class A common stock - $0.01 par value; 50,000,000 shares authorized; 0 and 175,000 issued, respectively	$0	$190.2M	$178.4M	$0
Class A common stock - $0.01 par value; 750,000,000 shares authorized; 117,603,806 and 116,575,773 shares issued, respectively	$1.2M	$1.2M
Additional paid-in-capital	$1.8B	$1.8B
Accumulated other comprehensive loss	-$2.6M	-$1.8M
Retained earnings (accumulated deficit)	-$1.3B	-$780.8M
Treasury stock, at cost; 5,971,712 and 1,537,582 shares issued, respectively	-$61.4M	-$21.1M
Total shareholders equity	$415.2M	$1.0B	$1.1B	$859.4M
Total liabilities, mezzanine equity and shareholders equity	$1.9B	$2.5B
Preferred class A common stock, par value (in dollars per share)	$0.01	$0.01
Preferred class A common stock, shares authorized (in shares)	50.0M shares	50.0M shares
Preferred class A common stock, shares issued (in shares)	0 shares	175.0K shares	175.0K shares	0 shares
Class A common stock, par value (in dollars per share)	$0.01	$0.01
Class A common stock, shares authorized (in shares)	750.0M shares	750.0M shares
Class A common stock, shares issued (in shares)	117.6M shares	116.6M shares
Treasury stock, shares issued (in shares)	6.0M shares	1.5M shares

Cash from operations¹⁰⁷⁸⁹⁵$38.8M in 2025

Share buybacks⁵$40.0M in 2025

Every line of the cash flow as filed: the last 3 fiscal years, latest first.⁵

Period ending	2025-12-31	2024-12-31	2023-12-31
Loss before preferred dividends and accretion of Series A Preferred Stock including excise tax	-$534.5M	-$61.6M	-$113.0M
Change in fair value of contingent consideration	$6.5M	$4.9M	$18.0M
(Gain) loss on disposal of non-strategic assets	-$14.9M	$0	$8.1M
(Gain) loss from equity method investees	-$365.0K	$3.4M	-$1.3M
Extinguishment of Series A Preferred Stock and other refinancing fees	$15.0M	$0	$0
Loss on option exercise	$52.5M	$0	$0
Depreciation and amortization expenses	$115.9M	$118.4M	$123.4M
Stock-based compensation expense	$39.7M	$39.7M	$40.5M
Deferred tax benefit	-$3.0M	-$3.0M	-$93.3M
Amortization of contract cost assets	$6.8M	$4.8M	$10.9M
Amortization of deferred financing costs	$7.8M	$3.5M	$3.8M
Goodwill impairment	$398.0M	$0	$0
Loss on extinguishment/repayment of debt, net	$3.5M	$0	$21.0M
Right-of-use asset impairment	$0	$2.6M	$24.1M
Loss on lease termination	$676.0K	$18.9M	$0
Change in tax receivables agreement liability	$804.0K	$173.0K	$62.0M
Right-of-use operating assets	$1.8M	$3.3M	$16.6M
Other current operating cash inflows (outflows), net	$0	$180.0K	-$171.0K
Accounts receivable, net and contract assets	$73.7M	$32.1M	-$164.7M
Prepaid expenses and other current and non-current assets	$5.0M	$4.5M	-$10.6M
Contract cost assets	-$7.0M	-$6.1M	-$5.6M
Accounts payable	$6.6M	$4.2M	-$6.7M
Accrued liabilities	$3.0M	-$24.2M	$23.7M
Operating lease liabilities	-$33.2M	-$15.0M	-$15.4M
Accrued compensation and employee benefits	$17.3M	-$22.7M	-$2.1M
Deferred revenue	-$1.3M	-$3.5M	-$263.0K
Reserve for claims and performance-based arrangements	-$126.5M	-$85.3M	$204.3M
Other long-term liabilities	$5.0M	-$653.0K	-$759.0K
Net cash and restricted cash provided by operating activities	$38.8M	$18.8M	$142.6M
Cash paid for asset acquisitions and business combinations	-$57.4M	-$30.7M	-$388.2M
Proceeds from disposal of non-strategic assets	$91.3M	$0	$577.0K
Return of equity method investments	$986.0K	$7.0K	$870.0K
Purchases of investments and contributions to equity method investees	-$1.0M	-$7.3M	$0
Investments in internal-use software and purchases of property and equipment	-$34.1M	-$24.9M	-$28.7M
Net cash and restricted cash used in investing activities	-$233.0K	-$62.9M	-$415.5M
Changes in working capital balances related to claims processing	-$42.9M	$43.5M	-$1.5M
Payment of contingent consideration	-$1.8M	-$70.4M	-$46.9M
Proceeds from stock option exercises	$0	$3.5M	$12.5M
Proceeds from issuance of preferred stock, net of offering costs	$0	$0	$168.0M
Proceeds from issuance of long-term debt, net of offering costs	$408.0M	$58.6M	$647.5M
Repayment of debt	-$343.0M	$0	-$464.2M
Repurchase of common stock	-$40.0M	$0	$0
Payment of preferred dividends	-$11.1M	-$20.1M	-$18.8M
Taxes withheld and paid for vesting of equity awards	-$5.2M	-$15.7M	-$15.3M
Net cash and restricted cash (used in) provided by financing activities	-$35.9M	-$565.0K	$281.3M
Effect of exchange rate on cash and cash equivalents and restricted cash	-$486.0K	-$229.0K	-$79.0K
Net increase (decrease) in cash and cash equivalents and restricted cash	$2.2M	-$45.0M	$8.3M

Compare Evolent Health, Inc. with another company

Leadership

Who has led Evolent Health, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

President

Seth Blackley2015–2020

Chief financial officer

Chief operating officer

20202025

Chief executive officerSeth Blackley Mar 3, 2021 to now¹⁴
Chief executive officerSteve Wigginton Feb 17, 2017 to Aug 3, 2017¹⁵
PresidentSeth Blackley Jun 5, 2015 to Jun 5, 2020¹⁶
Chief financial officerMario Ramos Jan 5, 2026 to now¹⁷
Chief financial officerNicholas McGrane Jun 5, 2015 to Mar 5, 2019¹⁸
Chief operating officerEmily Ann Rafferty Jul 13, 2023 to now¹⁹
Chief operating officerSteve Tutewohl Jul 2, 2020 to Apr 26, 2024²⁰

Board members and other officers (29)

Controller/Prin. Acct. OfficerAammaad Shams Jun 22, 2020 to now²¹
Cheif Financial OfficerNicholas McGrane May 12, 2017 to May 12, 2017²²
Chief Technology OfficerChad Pomeroy Jun 5, 2015 to Sep 15, 2016²³
Chief Accounting OfficerCynthia Cammett Cann Jun 5, 2015 to Jun 5, 2015²⁴
Chief Talent OfficerDave Thornton Jun 5, 2015 to Sep 15, 2016²⁵
Chief Medical OfficerGary Piefer Jun 5, 2015 to Jun 10, 2015²⁶
Chief Development OfficerSteve Wigginton Jun 5, 2015 to Sep 15, 2016²⁷
Principal Accounting OfficerLydia Stone Oct 5, 2015 to Mar 4, 2020²⁸
Board memberBrendan B. Springstubb Feb 14, 2025 to now²⁹
Board memberShawn M. Guertin Jun 9, 2025 to now³⁰
Board memberRussell Monroe Glass Feb 26, 2024 to now³¹
Board memberRichard M. Jelinek Jun 12, 2023 to now³²
Board memberToyin Ajayi Aug 3, 2023 to now³³
Board memberKim Keck Jan 20, 2021 to now³⁴
Board memberTunde Sotunde Nov 3, 2021 to Jun 12, 2023³⁵
Board memberPeter J. Grua Jan 31, 2020 to now³⁶
Board memberCraig A. Barbarosh Dec 30, 2020 to now³⁷
Board memberSeth Blackley May 9, 2018 to now³⁸
Board memberMary Bridget Duffy Sep 20, 2017 to Jun 10, 2024³⁹
Board memberMichael D'Amato Apr 20, 2016 to Jun 14, 2021⁴⁰
Board memberBruce C. Felt Jr. Jun 5, 2015 to Jun 11, 2020⁴¹
Board memberDavid Farner Jun 5, 2015 to Jun 13, 2022⁴²
Board memberDiane Holder Jun 5, 2015 to now⁴³
Board memberMatthew Hobart Jun 5, 2015 to Jun 5, 2015⁴⁴
Board memberMichael T. Kirshbaum Jun 5, 2015 to Jun 5, 2015⁴⁵
Board memberNorman C. Payson Md. Jun 5, 2015 to Jun 15, 2018⁴⁶
Board memberRobert W. Musslewhite Jun 5, 2015 to Jun 5, 2015⁴⁷
Board memberKenneth A. Samet Sep 3, 2015 to Aug 19, 2019⁴⁸
Board memberCheryl Scott Nov 4, 2015 to now⁴⁹

Named in SEC Form D filings

People the company listed in its private-offering notices.

Executive OfficerDANIEL MCCARTHY named May 26, 2023⁵⁰
Executive OfficerJOHN JOHNSON named Oct 15, 2021 to May 26, 2023⁵⁰
Executive OfficerJONATHAN WEINBERG named Oct 15, 2021 to May 26, 2023⁵⁰
DirectorBRIDGET DUFFY named Oct 15, 2021 to May 26, 2023⁵⁰
DirectorFRANK WILLIAMS named Oct 15, 2021 to May 26, 2023⁵⁰

Timeline

Mar 3, 2021New chief executive Seth Blackley becomes CEO¹⁴
Feb 17, 2017New chief executive Steve Wigginton becomes CEO¹⁵
Dec 12, 2014Founded Evolent Health, Inc. is founded²

Filings

361 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 68 major events, 170 insider forms, 47 large holders, 4 private raises, 52 other. The latest 20:

Sep 8, 2026SCHEDULE 13G/A EDGAR
Aug 28, 20264 EDGAR
Aug 26, 2026144 EDGAR
Aug 6, 202610-Q EDGAR
Aug 6, 20268-K EDGAR
Jul 17, 2026SCHEDULE 13G EDGAR
Jul 6, 20264 EDGAR
Jul 6, 20264 EDGAR
Jul 6, 20264 EDGAR
Jul 6, 20264 EDGAR
Jun 10, 2026S-8 EDGAR
Jun 8, 20264 EDGAR
Jun 8, 20264 EDGAR
Jun 8, 20264 EDGAR
Jun 8, 20264 EDGAR
Jun 8, 20264 EDGAR
Jun 8, 20264 EDGAR
Jun 8, 20264 EDGAR
Jun 8, 20264 EDGAR
Jun 8, 20264 EDGAR

The 361 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

57 open-market trades by officers, directors and large owners since October 2021: 11 buys and 46 sales. Grants, option exercises and gifts are left out.

Date	Who	Trade	Shares	Price	Value	Filing
Aug 26, 2026	McCarthy Daniel JosephPRESIDENT	Sale	65,892	$5.00	$329.5K	Form 4
Nov 18, 2025	Springstubb Brendan BDirector	Buy	10,000	$3.82	$38.2K	Form 4
Mar 7, 2025	Jelinek Richard MDirector	Buy	30,000	$9.12	$273.8K	Form 4
Mar 7, 2025	Springstubb Brendan BDirector	Buy	15,000	$9.27	$139.1K	Form 4
Mar 7, 2025	KECK KIMDirector	Buy	10,540	$9.44	$99.5K	Form 4
Mar 6, 2025	Holder DianeDirector	Buy	2,735	$9.33	$25.5K	Form 4
Mar 6, 2025	McCarthy Daniel JosephPRESIDENT	Buy	11,040	$9.01	$99.5K	Form 4
Mar 6, 2025	GRUA PETER JDirector	Buy	11,040	$9.01	$99.5K	Form 4
Mar 6, 2025	Blackley SethChief Executive Officer	Buy	55,225	$9.01	$497.6K	Form 4
Mar 6, 2025	Glass Russell MonroeDirector	Buy	5,400	$9.27	$50.1K	Form 4
Mar 6, 2025	Barbarosh Craig A.Director	Buy	2,000	$8.81	$17.6K	Form 4
Mar 4, 2025	Springstubb Brendan BDirector	Buy	5,000	$8.75	$43.8K	Form 4
Aug 23, 2024	McCarthy Daniel JosephPRESIDENT	Sale	10,469	$32.38	$339.0K	Form 4
Aug 22, 2024	McCarthy Daniel JosephPRESIDENT	Sale	23,693	$30.89	$731.8K	Form 4
Aug 22, 2024	Weinberg JonathanGeneral Counsel	Sale	42,140	$31.20	$1.3M	Form 4
Aug 22, 2024	Blackley SethChief Executive Officer	Sale	187,904	$30.00	$5.6M	Form 4
Aug 22, 2024	Johnson John PaulChief Financial Officer	Sale	44,693	$30.00	$1.3M	Form 4
Aug 22, 2024	Rafferty Emily AnnChief Operating Officer	Sale	8,861	$30.00	$265.8K	Form 4
Dec 5, 2023	Blackley SethChief Executive Officer	Sale	141,000	$26.54	$3.7M	Form 4
Nov 15, 2023	McCarthy Daniel JosephPRESIDENT	Sale	11,000	$30.00	$330.0K	Form 4

All 57 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Morgan StanleySCHEDULE 13G/A, 3 filings Aug 6, 2025 to Sep 8, 2026⁵¹
BlackRock Portfolio Management LLCSCHEDULE 13G, 1 filing Jul 17, 2026⁵²
VANGUARD GROUP INCSCHEDULE 13G/A, 5 filings Feb 10, 2022 to Mar 26, 2026⁵³
EVENTIDE ASSET MANAGEMENT, LLCSCHEDULE 13G/A, 4 filings May 14, 2025 to Feb 13, 2026⁵⁴
FMR LLCSCHEDULE 13G/A, 7 filings Apr 10, 2023 to Feb 5, 2026⁵⁵
Adam BoehlerSCHEDULE 13G, 1 filing Nov 14, 2025⁵⁶
Durable Capital Partners LPSCHEDULE 13G/A, 2 filings Jul 7, 2025 to Nov 14, 2025⁵⁷
Wellington Management CompanySCHEDULE 13G/A, 4 filings Feb 8, 2024 to Jul 7, 2025⁵⁸
CADIAN CAPITAL MANAGEMENT, LPSCHEDULE 13G, 1 filing May 15, 2025⁵⁹
RA CAPITAL MANAGEMENT, L.P.SCHEDULE 13G/A, 2 filings Jun 17, 2024 to Feb 14, 2025⁶⁰
JPMorgan ChaseSC 13G/A, 4 filings Jan 10, 2022 to Apr 9, 2024⁶¹
UpmcSC 13G/A, 2 filings Feb 3, 2023 to Mar 8, 2023⁶²
Granahan Investment Management, LLCSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 2023⁶³
Engaged Capital LLCSC 13D/A, 3 filings May 9, 2022 to Aug 25, 2022⁶⁴
ENGAGED CAPITAL I LPSC 13D/A, 1 filing Nov 5, 2021⁶⁵

Money raised

Private offerings the company reported to the SEC on Form D.

May 11, 2023Raised $727,985 in a private offering of equity Form D: 18 investors so far Form D
Aug 1, 2022Raised $125 million in a private offering of equity Form D: $182 million offered in all Form D
Nov 15, 2021Raised $450,000 in a private offering of equity Form D: 18 investors so far Form D
Oct 1, 2021Raised $42.5 million in a private offering of equity Form D: $65 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
BlackRock, Inc.	14,814,851	$80.3M	0.0%	+3,925,979
Cadian Capital Management, LP	10,814,473	$58.6M	4.4%	No change
Morgan Stanley	8,969,012	$48.6M	0.0%	−112,067
UBS Group AG	6,245,283	$33.8M	0.0%	−1,905,078
Rubicon Founders LLC	5,816,123	$31.5M	16.0%	No change
Engaged Capital LLC	5,563,912	$30.2M	9.3%	No change
D. E. Shaw & Co., Inc.	5,107,561	$27.7M	0.0%	−326,471
Vanguard Capital Management LLC	4,787,994	$26.0M	0.0%	−79,409
Marshall Wace, Llp	3,413,245	$18.5M	0.0%	+2,628,233
Nuveen, LLC	3,132,085	$17.0M	0.0%	+2,866,943
Geode Capital Management, LLC	2,904,912	$15.7M	0.0%	+286,487
Rock Springs Capital Management LP	2,500,000	$13.6M	0.7%	−175,000
State Street Corp	2,460,431	$13.3M	0.0%	−185,967
Charles Schwab Investment Management Inc	2,131,573	$11.6M	0.0%	+182,127
Goldman Sachs Group Inc	1,745,852	$9.5M	0.0%	−490,754
Rock Point Advisors, LLC	1,719,886	$9.3M	2.3%	−66,795
Jacobs Levy Equity Management, Inc	1,601,638	$8.7M	0.0%	+991,536
Kennedy Capital Management LLC	1,567,816	$8.5M	0.2%	−29,799
Vanguard Portfolio Management LLC	1,347,822	$7.3M	0.0%	+416,944
Healthcare Of Ontario Pension Plan Trust Fund	1,276,800	$6.9M	0.0%	New
Two Sigma Investments, LP	1,263,653	$6.8M	0.0%	+392,160
Northern Trust Corp	1,003,245	$5.4M	0.0%	+86,108
Hudson Bay Capital Management LP	913,109	$4.9M	0.0%	−403,311
Bank Of America Corp /de/	875,398	$4.7M	0.0%	+594,544
Bnp Paribas Financial Markets	860,358	$4.7M	0.0%	−31,045

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

1 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

Date	Member	Trade	Amount	Vs S&P since	Filing
May 11, 2020	Greg Gianforte, House	Sale	$50,001 - $100,000	+198.7%	Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGAREvolent Health, Inc. filings on SEC EDGAR
2
GLEIFEvolent Health, Inc. LEI record (549300CZOCFHQ2BBTR11)
3
SEC EDGAREvolent Health, Inc. filings on SEC EDGAR
4
SEC EDGAREvolent Health, Inc. annual report, Item 1 (Business)
5
SEC EDGAREvolent Health, Inc. 10-K for fiscal 2025
6
SEC EDGAREvolent Health, Inc. 10-K for fiscal 2019
7
SEC EDGAREvolent Health, Inc. 10-K for fiscal 2020
8
SEC EDGAREvolent Health, Inc. 10-K for fiscal 2021
9
SEC EDGAREvolent Health, Inc. 10-K for fiscal 2022
10
SEC EDGAREvolent Health, Inc. 10-K for fiscal 2019
11
SEC EDGAREvolent Health, Inc. 10-Q for fiscal 2026
12
SEC EDGAREvolent Health, Inc. 10-Q for fiscal 2026
13
SEC EDGAREvolent Health, Inc. 10-K for fiscal 2019
14
SEC EDGARSeth Blackley, Chief executive officer
15
SEC EDGARSteve Wigginton, Chief executive officer
16
SEC EDGARSeth Blackley, President
17
SEC EDGARMario Ramos, Chief financial officer
18
SEC EDGARNicholas McGrane, Chief financial officer
19
SEC EDGAREmily Ann Rafferty, Chief operating officer
20
SEC EDGARSteve Tutewohl, Chief operating officer
21
SEC EDGARAammaad Shams, Controller/Prin. Acct. Officer
22
SEC EDGARNicholas McGrane, Cheif Financial Officer
23
SEC EDGARChad Pomeroy, Chief Technology Officer
24
SEC EDGARCynthia Cammett Cann, Chief Accounting Officer
25
SEC EDGARDave Thornton, Chief Talent Officer
26
SEC EDGARGary Piefer, Chief Medical Officer
27
SEC EDGARSteve Wigginton, Chief Development Officer
28
SEC EDGARLydia Stone, Principal Accounting Officer
29
SEC EDGARBrendan B. Springstubb, Board member
30
SEC EDGARShawn M. Guertin, Board member
31
SEC EDGARRussell Monroe Glass, Board member
32
SEC EDGARRichard M. Jelinek, Board member
33
SEC EDGARToyin Ajayi, Board member
34
SEC EDGARKim Keck, Board member
35
SEC EDGARTunde Sotunde, Board member
36
SEC EDGARPeter J. Grua, Board member
37
SEC EDGARCraig A. Barbarosh, Board member
38
SEC EDGARSeth Blackley, Board member
39
SEC EDGARMary Bridget Duffy, Board member
40
SEC EDGARMichael D'Amato, Board member
41
SEC EDGARBruce C. Felt Jr., Board member
42
SEC EDGARDavid Farner, Board member
43
SEC EDGARDiane Holder, Board member
44
SEC EDGARMatthew Hobart, Board member
45
SEC EDGARMichael T. Kirshbaum, Board member
46
SEC EDGARNorman C. Payson Md., Board member
47
SEC EDGARRobert W. Musslewhite, Board member
48
SEC EDGARKenneth A. Samet, Board member
49
SEC EDGARCheryl Scott, Board member
50
SEC EDGAREvolent Health, Inc. Form D naming DANIEL MCCARTHY
51
SEC EDGARMorgan Stanley SCHEDULE 13G/A on Evolent Health, Inc.
52
SEC EDGARBlackRock Portfolio Management LLC SCHEDULE 13G on Evolent Health, Inc.
53
SEC EDGARVANGUARD GROUP INC SCHEDULE 13G/A on Evolent Health, Inc.
54
SEC EDGAREVENTIDE ASSET MANAGEMENT, LLC SCHEDULE 13G/A on Evolent Health, Inc.
55
SEC EDGARFMR LLC SCHEDULE 13G/A on Evolent Health, Inc.
56
SEC EDGARAdam Boehler SCHEDULE 13G on Evolent Health, Inc.
57
SEC EDGARDurable Capital Partners LP SCHEDULE 13G/A on Evolent Health, Inc.
58
SEC EDGARWellington Management Company SCHEDULE 13G/A on Evolent Health, Inc.
59
SEC EDGARCADIAN CAPITAL MANAGEMENT, LP SCHEDULE 13G on Evolent Health, Inc.
60
SEC EDGARRA CAPITAL MANAGEMENT, L.P. SCHEDULE 13G/A on Evolent Health, Inc.
61
SEC EDGARJPMorgan Chase SC 13G/A on Evolent Health, Inc.
62
SEC EDGARUpmc SC 13G/A on Evolent Health, Inc.
63
SEC EDGARGranahan Investment Management, LLC SC 13G/A on Evolent Health, Inc.
64
SEC EDGAREngaged Capital LLC SC 13D/A on Evolent Health, Inc.
65
SEC EDGARENGAGED CAPITAL I LP SC 13D/A on Evolent Health, Inc.